Study on Evaluating the Effectiveness of Statins in the Treatment of Moyamoya Disease

Last updated: February 4, 2025
Sponsor: Beijing Tiantan Hospital
Overall Status: Active - Recruiting

Phase

N/A

Condition

Moyamoya Syndrome

Treatment

Revascularization/Conservative management

Clinical Study ID

NCT06817434
KY2023-297-02
  • Ages 18-60
  • All Genders

Study Summary

The purpose of this study is to investigate the effectiveness of statins in the treatment of moyamoya disease based on multimodal magnetic resonance imaging.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. The imaging examination meets the diagnostic criteria for moyamoya disease;

  2. Sign the informed consent form;

  3. Age ≥18 years old;

  4. Baseline mRS score ≤2 points;

  5. The patient receives revascularization/conservative treatment;

  6. There is at least 1 imaging follow-up result.

Exclusion

Exclusion Criteria:

  1. Patients with atherosclerosis, autoimmune diseases, meningitis, Down syndrome,cranial trauma, or those who have undergone radioactive head irradiation, as theseconditions may lead to secondary cerebrovascular disease and contribute to thedevelopment of Moyamoya syndrome;

  2. Individuals under the age of 18;

  3. Participants who refuse to take part in this study;

  4. Pregnant patients;

  5. Those with concurrent intracranial aneurysms, cerebrovascular malformations, braintumors, or hydrocephalus;

  6. A history of stroke occurring more than three months prior to the diagnosis ofMoyamoya disease;

  7. Individuals with a history of coronary heart disease or previous cardiovascular andcerebrovascular surgical interventions, including cerebral revascularization,intracranial artery stent implantation, carotid artery stenting, endarterectomy,coronary artery bypass grafting, or coronary stent implantation;

  8. Allergies to contrast media;

  9. Patients with missing imaging data or whose image quality cannot be analyzed;

  10. Individuals who refuse or are unable to undergo imaging follow-up;

  11. Patients receiving other types of lipid-lowering drug treatments.

Study Design

Total Participants: 330
Treatment Group(s): 1
Primary Treatment: Revascularization/Conservative management
Phase:
Study Start date:
December 15, 2024
Estimated Completion Date:
December 31, 2026

Connect with a study center

  • Beijing Tiantan Hospital

    Beijing, 100070
    China

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.